FCAHS

EpiMedTech Global to Present Revolutionary Epigenetics Research at MedInvest Biotech & Pharma Investor Conference

Retrieved on: 
Martedì, Aprile 2, 2024
Conference, Gene expression, Syndrome, FRSC, DNA, Cancer, DNA methylation, Embryo, FCAHS, HKG, Ageing, Vaccine

The presentation will spotlight groundbreaking advancements in DNA methylation and its significant potential in transforming global healthcare through early disease detection.

Key Points: 
  • The presentation will spotlight groundbreaking advancements in DNA methylation and its significant potential in transforming global healthcare through early disease detection.
  • DNA methylation, a critical process in epigenetic signaling, acts as a sophisticated regulatory mechanism, controlling gene expression without altering the DNA sequence itself.
  • "EpiMedTech Global is at the forefront of leveraging DNA methylation for early disease detection, aiming to bridge the vast gap between the potential of epigenetic research and its current clinical application," said Prof. Szyf.
  • Join us at MedInvest to discover how EpiMedTech Global is paving the way for a future where early detection and prevention are within reach for everyone, everywhere.

Recognizing and Celebrating Outstanding Contributions to the Canadian Cancer Research Community

Retrieved on: 
Lunedì, Novembre 6, 2023
Women of Outstanding Achievement Photographic Exhibition, FRSC, ISCB Senior Scientist Award, Order of Ontario, FCAN, Medical research, Myeloma Canada, Molecular biology, Multiple myeloma, FRS, Genetics, Jewish General Hospital, Psycho-oncology, RN, Conference, Organization, Federation, Doctor of Philosophy, FRCPC, Doctor of Science, University of Hong Kong, Research, Toronto Metropolitan University, Patient, Senior, McGill University, Princess Margaret Cancer Centre, Professor, University of Toronto, Immune system, Canadian Partnership Against Cancer, University, OC, FCAHS, Palliative care, Distinguished Service to Music Medal, CCRA, Toronto, Breast cancer, University Health Network, University of Manitoba, Ovarian Cancer Research Alliance, Pharmaceutical industry, Nursing, Management, MD, Pharmacology, Cancer

TORONTO, Nov. 6, 2023 /CNW/ - Today, the Canadian Cancer Research Alliance (CCRA) announces the recipients of its biennial awards, recognizing significant contributions to cancer research in Canada.

Key Points: 
  • TORONTO, Nov. 6, 2023 /CNW/ - Today, the Canadian Cancer Research Alliance (CCRA) announces the recipients of its biennial awards, recognizing significant contributions to cancer research in Canada.
  • Awardees will be honoured at the Canadian Cancer Research Conference, which is taking place in Halifax from November 12 to 14.
  • Initiated in 2011, the CCRA Awards acknowledge and celebrate the contributions of individuals who have had a remarkable impact on cancer research and the cancer research community, as well as those who have shown exceptional leadership in patient involvement in cancer research.
  • The Canadian Cancer Research Alliance (CCRA) is an alliance of organizations that collectively fund most of the cancer research conducted in Canada – research that will lead to better ways to prevent, diagnose, and treat cancer, and improve patient and survivor outcomes.

Overcoming culture of caution key to achieving greater health data sharing in Canada: Expert Panel report

Retrieved on: 
Giovedì, Ottobre 19, 2023
FRSC, Health, CCA, British Columbia Basic Income Expert Panel Report, Organization, Doctor of Philosophy, Population health, Research, Social stigma, Dots, Risk, Digital divide, Privacy, Public, Culture, Patient, Bias, Failure, FCAHS, Pharmaceutical industry

OTTAWA, Oct. 19, 2023 (GLOBE NEWSWIRE) -- The barriers to greater health data sharing in Canada are fundamentally social and political, and a new CCA expert panel report details how overcoming this culture of caution could yield significant benefits for patients, researchers, and healthcare providers.

Key Points: 
  • OTTAWA, Oct. 19, 2023 (GLOBE NEWSWIRE) -- The barriers to greater health data sharing in Canada are fundamentally social and political, and a new CCA expert panel report details how overcoming this culture of caution could yield significant benefits for patients, researchers, and healthcare providers.
  • Connecting the Dots shows how it’s possible to protect the privacy of patients while achieving robust data sharing systems and that a continued absence of improved health data sharing could deepen existing negative impacts.
  • Canada excels at health data sharing for research purposes and has the opportunity—with broad coordination—to build on the experience of existing, smaller scale domestic health data sharing networks and learn from data-sharing initiatives abroad.
  • However, failure to improve health data sharing could exacerbate existing health inequalities, hinder public health monitoring and interventions, and limit opportunities for new research and innovation.

Expert Panel describes path to bring critical antibiotics to Canadian market

Retrieved on: 
Giovedì, Settembre 7, 2023
Human, CDN, FRSC, Failure, Face, Infection, Research, CCA, Medicine, Doctor of Philosophy, British Columbia Basic Income Expert Panel Report, Death, US, Panel, Risk, FCAHS, Public Health Agency of Canada, Transplant, Health, Public Health Agency, Vaccine, Pharmaceutical industry, Resistance

Canada is lagging behind peer countries on access to existing drugs, and a new expert panel report describes a pathway to a more stable supply of antimicrobials in the future.

Key Points: 
  • Canada is lagging behind peer countries on access to existing drugs, and a new expert panel report describes a pathway to a more stable supply of antimicrobials in the future.
  • “The consequences of antimicrobial resistance are real and growing, while at the same time, companies are leaving the commercial space,” said Andrew M. Morris, M.D., Chair of the Expert Panel.
  • The cumulative costs to Canadian healthcare systems could reach $120 billion by 2050 as resistance rates increase.
  • Overcoming Resistance describes the challenges Canada faces when accessing high-value antimicrobials and describes pull incentives that could help bring existing antimicrobials to market and encourage the development of new ones.

AUA Leadership Program Announces 2023 Class

Retrieved on: 
Martedì, Aprile 4, 2023
FRCSC, AUA, American Urological Association, Medicine, Mentorship, Urology, FCAHS, FACS, Presidents Leadership Class, Management, MD

BALTIMORE, April 4, 2023 /PRNewswire/ -- The American Urological Association (AUA) announced today the newest members of the 2023 AUA Leadership Program.

Key Points: 
  • BALTIMORE, April 4, 2023 /PRNewswire/ -- The American Urological Association (AUA) announced today the newest members of the 2023 AUA Leadership Program.
  • The 2023-2024 program year marks the 10th Leadership Class, and with this class, the AUA will top 200 participants in this flagship program.
  • The AUA Leadership Program is designed for urologists who have displayed leadership skills within organized medicine and is one of the most acclaimed and longstanding of AUA's leadership initiatives.
  • Congratulations to the 2023 class of the AUA Leadership Program:

Council of Canadian Academies (CCA) - Advances in digital technology outpacing efforts to address online harms: expert panel report

Retrieved on: 
Giovedì, Marzo 30, 2023
Survivor, Private sector, FRSC, Internet, Law enforcement, Policy, Public Safety Canada, CCA, Privacy, Doctor of Philosophy, British Columbia Basic Income Expert Panel Report, Council, FCAHS, Ecosystem

While the internet and communications technologies are essential and often helpful, they also enable malicious actors to harm people and communities.

Key Points: 
  • While the internet and communications technologies are essential and often helpful, they also enable malicious actors to harm people and communities.
  • Addressing these harms requires both legal and non-legal approaches that can keep pace with technological change and protect privacy and human rights.
  • “Digital technologies have become necessary for accessing virtually all essential services, making everyone, even those not actively online, susceptible to cyber-related crimes and harms,” said Jennifer Stoddart, O.C., C.Q., Ad.E., Chair of the Expert Panel.
  • Not all online harm stems from unlawful behaviours, however, and regulation isn’t the only means to keep people safe in the digital age.

Tonix Pharmaceuticals Announces Publication of Paper in Viruses Highlighting the Company’s Development of a Vaccine to Protect Against Monkeypox and Smallpox (TNX-801)

Retrieved on: 
Giovedì, Febbraio 9, 2023
Research, Infection, Immunity, University of Alberta Faculty of Medicine and Dentistry, Smallpox, FCAHS, Tonix Pharmaceuticals, Vaccine, Animal, RPV, Vaccination, Primate, Monkeypox, Severe acute respiratory syndrome coronavirus 2, Faculty, Virus, Monkeypox virus, University, Professor, Dentistry, Medicine

CHATHAM, N.J, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the publication of a paper entitled, “Single Dose of Recombinant Chimeric Horsepox Virus (TNX‐801) Vaccination Protects Macaques from Lethal Monkeypox Challenge,” in the journal Viruses. The publication demonstrates that a single dose vaccination with TNX‐801 was effective at protecting non-human primates from infection with monkeypox virus. The article can be accessed online at https://www.mdpi.com/1999-4915/15/2/356.

Key Points: 
  • The publication demonstrates that a single dose vaccination with TNX‐801 was effective at protecting non-human primates from infection with monkeypox virus.
  • “The global monkeypox outbreak that started in the spring of 2022 reinforced the importance of protecting the population using live virus vaccines,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals.
  • “Consequently, there is a need for an effective and safer, single dose, live replicating vaccine against monkeypox virus.
  • Synthetic horsepox virus is the basis for the Company’s TNX-801 vaccine in development to protect against monkeypox and smallpox and for the Company’s Recombinant Pox Virus (RPV) platform to protect against other pathogens, including SARS-CoV-2.

Expert Panel lays out costly consequences of misinformation

Retrieved on: 
Giovedì, Gennaio 26, 2023
Policy, Public policy, Health, British Columbia Basic Income Expert Panel Report, Socioeconomic impact of female education, Council, Fault line, Innovation, Science and Economic Development Canada, COVID-19, FCAHS, Hospital, CCA, Economic development, Literacy, FRSC, Death, Climate change, Doctor of Philosophy, Management, Pharmaceutical industry, Science

“Misinformation has become a global problem and a defining issue of our time,” said Alex Himelfarb, PhD, Chair of the Expert Panel.

Key Points: 
  • “Misinformation has become a global problem and a defining issue of our time,” said Alex Himelfarb, PhD, Chair of the Expert Panel.
  • The Expert Panel on the Socioeconomic Impacts of Science and Health Misinformation estimates that misinformation cost the Canadian healthcare system at least $300 million during nine months of the COVID-19 pandemic in 2021.
  • Fault Lines details how science and health misinformation spreads and its impacts on individuals, communities, and society.
  • It explores what makes people susceptible to misinformation messaging and how we might use these insights to improve societal resilience.

Bresotec’s BresoDX1 for At-Home Sleep Apnea Testing Receives FDA 510(k) Clearance

Retrieved on: 
Martedì, Gennaio 3, 2023
Biotechnology, FDA, Medical Devices, Health, Medical Supplies, Polysomnography, Food, Motion, Medicine, MD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Sleep apnea, Sleep, FCAHS, Patient, Central sleep apnea, Heart rate, CPT, PSG, FRCP, Physician, Hypopnea, Neck, Diagnosis, Collection, Trachea, Medical device, Medical imaging, Oxygen saturation (medicine)

Bresotec Medical (“Bresotec” or the “Company”), a medical device company that develops, manufactures, and markets non-invasive portable diagnostic devices for accurate at-home diagnosis of sleep apnea, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for BresoDX1, its initial product for at-home sleep apnea testing.

Key Points: 
  • Bresotec Medical (“Bresotec” or the “Company”), a medical device company that develops, manufactures, and markets non-invasive portable diagnostic devices for accurate at-home diagnosis of sleep apnea, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for BresoDX1, its initial product for at-home sleep apnea testing.
  • BresoDX1 is indicated for use to aid in the diagnosis of moderate to severe sleep apnea in adults in an at-home setting.
  • Once data is uploaded to the BresoDX1 software, BresoDX1 offers clinicians a reliable, turnkey diagnostic tool with fully transparent reporting.
  • The company plans to market BresoDX1 through its internal commercial salesforce and will initially target sleep physicians and sleep centers throughout the United States.

Enhancing and protecting Canada's carbon stocks is essential but insufficient to meet GHG emission targets: expert panel report

Retrieved on: 
Martedì, Dicembre 6, 2022
Carbon, Erosion, Royal Society, Royal, Canadian Academy of Health Sciences, Disturbance, Biodiversity, Climate Solutions Caucus, Council, Water quality, Fellows, Government, Climate change, Soil, Public policy, Canadian Academy of Engineering, FCAHS, Ecosystem, Forest, Climate, Environment and Climate Change Canada, Doctor of Philosophy, CCA, FRSC, Tobacco Products Scientific Advisory Committee, Wetland, GHG, Atmosphere, Organization, Western Ghats Ecology Expert Panel, Risk, Outline of health sciences, Attention, Greenhouse gas, Indigenous self-government in Canada, Agriculture, Renewable energy, Engineering

“On a global scale, the carbon stored in Canada’s forests, wetlands, grasslands, and coastlines is quite significant,” said Glen MacDonald PhD, FRSC, Chair of the Expert Panel.

Key Points: 
  • “On a global scale, the carbon stored in Canada’s forests, wetlands, grasslands, and coastlines is quite significant,” said Glen MacDonald PhD, FRSC, Chair of the Expert Panel.
  • The Expert Panel on Canada’s Carbon Sink Potential determined that NBCSs can provide a way to protect, restore, and manage ecosystems that sequester carbon and help the government to meet its climate goals.
  • The CCA is a not-for-profit organization that undertakes independent, evidence-based expert panel assessments to inform public policy development in Canada.
  • The CCA's founding Academies also provide key guidance and input throughout the assessment process, including expert panel nominations and dissemination processes.